scPharmaceuticals

SCPH

Market cap $302M

Overview Fund Activity

5.63 USD

0.00

0%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

5.63

0.00

0%

1 day

0%

5 days

1.08%

1 month

17.29%

3 months

40.75%

6 months

86.42%

Year to date

57.7%

1 year

6.03%

5 years

-26.41%

10 years

-60.07%

About: scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.

Employees: 96

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

47% more capital invested

Capital invested by funds: $98.7M [Q1] → $146M (+$46.8M) [Q2]

8% more funds holding

Funds holding: 88 [Q1] → 95 (+7) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

9% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 32

2.32% less ownership

Funds ownership: 74.67% [Q1] → 72.35% (-2.32%) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$6

7% upside

Avg. target

$6

7% upside

High target

$6

7% upside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

Craig-Hallum

Chase Knickerbocker

$6

Hold

Downgraded

26 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about SCPH published over the past 30 days

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of scPharmaceuticals Inc. (NasdaqGS: SCPH) to MannKind Corporation (NasdaqGM: MNKD). Under the terms of the proposed transaction, shareholders of scPharmaceuticals would receive a cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specifi.

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of Shareholders

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of Shareholders

SCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKind

MONSEY, N.Y., Aug. 25, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the sale of scPharmaceuticals, Inc. (Nasdaq: SCPH) (“SCPH”) to MannKind Corporation (“MannKind”) for $5.35 per share in cash, plus one non-tradable contingent value right (“CVR”) per share offering milestone-based payments of up to $1.00 per share.

SCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKind

SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of scPharmaceuticals Inc. (NASDAQ: SCPH) to MannKind Corporation is fair to scPharmaceuticals shareholders. Under the terms of the proposed transaction, scPharmaceuticals shareholders would receive a cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in c.

SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders

Shareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating scPharmaceuticals (NASDAQ: SCPH) for possible breaches of fiduciary duty and other violations of law in its transaction with MannKind. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of scPharmaceuticals will receive $5.35 per share in cash plus contingent value rights worth up to $1.0.

Shareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public Shareholders

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

DANBURY, Conn. and BURLINGTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and scPharmaceuticals Inc. (Nasdaq: SCPH) today announced the signing of a definitive merger agreement for MannKind to acquire scPharmaceuticals.

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111

BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, announced today that it has received five Notices of Allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering their latest furosemide formulation, SCP-111. The SCP-111 formulation is the subject of a supplemental NDA expected to be filed by the Company this quarter. The five patents, once issued, will join four additional patents owned by the Company that cover the SCP-111 formulation.

scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111

scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants John Mohr - Senior Vice President of Clinical Development & Medical Affairs John H. Tucker - President, CEO, Principal Executive Officer & Director Rachael Nokes - Chief Financial Officer Steve C.

scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript

Zacks Investment Research

scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates

scPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.44 per share a year ago.

scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates

The Motley Fool

SCPH Revenue Up 99%

SCPH Revenue Up 99%

SCPH Revenue Up 99%

See News Rankings

Charts implemented using Lightweight Charts™